Drugs Made In America Acquisition II Corp. (DMII) Payables (2024 - 2026)

Drugs Made In America Acquisition (DMII) has reported Payables for 3 consecutive years, with $462253.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Payables changed N/A year-over-year to $462253.0 in Q2 2026; TTM through Jun 2026 was $462253.0, a N/A change from a year earlier, with the FY2025 full-year figure at $99359.0, down 60.27% from the prior year.
• Payables was $462253.0 for Q2 2026 at Drugs Made In America Acquisition, up from $99359.0 in the prior quarter.
• Over five years, Payables peaked at $462253.0 in Q2 2026 and troughed at $4592.0 in Q3 2025.
• A 3-year average of $204076.0 and a median of $174729.5 in 2024 frame the typical range for Payables.
• The widest YoY moves for Payables: up 60.27% in 2025, down 60.27% in 2025.
• Over 3 years, Payables stood at $250100.0 in 2024, then slumped by 60.27% to $99359.0 in 2025, then surged by 365.24% to $462253.0 in 2026.
• The last three Payables figures came in at $462253.0 (Q2 2026), $99359.0 (Q4 2025), and $4592.0 (Q3 2025), per Business Quant data.